Ganciclovi Sodium CAS 107910-75-8 Good Quality High Purity

• Customization: Available
• CAS No.: 107910-75-8
• Formula: C9h14n5nao4
• Model NO.: CAS 107910-75-8
• EINECS: 641-368-8
• Appearance: Powder
• Quality: Industrial
• Colour: White
• Transport Package: Drum
• Specification: 99%
• Trademark: Puyer
• Origin: China
• Production Capacity: 10000kg/Month

Product Description

Product Description

Ganciclovi Sodium

Chemical and Pharmacological Properties

• Chemical Name: 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine monosodium salt

• Mechanism of Action: Nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated to ganciclovi triphosphate, which competitively incorporates into viral DNA, causing chain termination and inhibiting replication.

• Spectrum of Activity:

  • Cytomegalovirus (CMV) (primary indication)

  • Herpes simplex virus (HSV-1, HSV-2) (less commonly)

  • Epstein-Barr virus (EBV) and Varicella-zoster virus (VZV) (limited efficacy)

Indications

1. CMV Retinitis (in immunocompromised patients, especially AIDS).

2. CMV Prevention/Treatment in organ transplant recipients.

3. Off-label Uses:

   • CMV colitis/pneumonitis in HIV patients.

   • Congenital CMV infection (investigational).

Dosage and Administration

• IV Form (Ganciclovi Sodium):

  • Induction: 5 mg/kg IV every 12h for 14-21 days.

  • Maintenance: 5 mg/kg IV daily or 6 mg/kg IV 5×/week.

• Dose Adjustment: Required for renal impairment (CrCl <80 mL/min).

Adverse Effects

• Hematologic:

  • Neutropenia (most common, up to 40% of patients).

  • Thrombocytopenia, anemia (dose-dependent).

• Other Common Effects:

  • Fever, rash, GI disturbances (nausea, diarrhea).

  • Elevated liver enzymes (AST/ALT).

• Serious Risks:

  • Bone marrow suppression (may require G-CSF).

  • Seizures (rare, high-dose therapy).

Contraindications

• Hypersensitivity to ganciclovi.

• Absolute neutrophil count (ANC) <500 cells/μL.

• Pregnancy (Category D)-Teratogenic in animals.
   

Detailed Photos